Close menu




BIONTECH SE SPON. ADRS 1

Photo credits: pixabay.com

Commented by André Will-Laudien on October 31st, 2022 | 13:31 CET

Top biotech shares - Now on the up: Bayer, Cardiol Therapeutics, BioNTech, Pfizer

  • Biotechnology
  • Cancer
  • Covid19

The fight against the two "common diseases" of cancer and cardiovascular disease continues with a major infusion of resources. In early 2022, President Biden announced a new edition of the "Cancer Moonshot" and named new goals: To halve the cancer death rate within 25 years and significantly improve the lives of people with cancer. The most common cause of death in Germany, on the other hand, is cardiovascular disease. With around 338,000 deaths in 2020, it accounted for more than a third of the 985,500 deaths. The second most common cause of death was primarily cancer, followed by diseases of the respiratory system. The biotech industry thus continues to face major challenges. Who is well positioned?

Read

Commented by Fabian Lorenz on October 28th, 2022 | 12:54 CEST

BioNTech, Nel ASA and Desert Gold - Ripe for uptrend?

  • Mining
  • Gold
  • Hydrogen
  • Biotechnology

The profit warning at ITM Power sent shockwaves throughout the hydrogen sector. Does this mean that the friendly development of the Nel share of the past few days has already ended? Analysts see little potential, at least at present, but are optimistic for the long term. Goldman Sachs is also optimistic about the gold price. At least the chances for a rise to over USD 2,000 are better than for a renewed decline. Producers like Barrick Gold should profit from this, and explorers like Desert Gold even disproportionately. At BioNTech, there is currently no impetus for an upward trend, and analysts' price targets diverge considerably. However, rumors from the US are encouraging.

Read

Commented by Stefan Feulner on October 26th, 2022 | 10:15 CEST

BioNTech, Defence Therapeutics, MorphoSys - The rebound is on the way

  • Biotechnology
  • Investments

The biotech sector is a growth market and, therefore, extremely capital-intensive. Due to the stricter monetary policy of the central banks, investors have given the promising sector the cold shoulder in recent months. Sector indices lost around 30% of their value, while the prices of individual stocks with a full development pipeline halved. The fact that several promising long-term companies are already trading below their cash levels shows that the panic is exaggerated. There are signs of a bottoming out, which could herald the next upward wave.

Read

Commented by Stefan Feulner on October 25th, 2022 | 14:43 CEST

Core One Labs, XPhyto, BioNTech - The second biotech series moves forward

  • Biotechnology

The enormously rapid development of the various COVID vaccines by historical standards showed how important biotechnology already is for humanity. Previously unknown companies such as BioNTech, Valneva and CureVac took center stage on the stock market and were able to multiply their share prices within a few months. Even after the pandemic, the biotech wheel continues to turn. Enormous growth opportunities are said to exist in the market for psychedelic drugs. Here, young growth companies are waiting in the wings with the potential to multiply their share prices in the future.

Read

Commented by Fabian Lorenz on October 19th, 2022 | 11:51 CEST

The problem solvers: Plug Power, BioNTech, Almonty Industries

  • Mining
  • Tungsten
  • Hydrogen
  • Biotechnology

Rarely have there been as many global crises and challenges as there are right now. In addition to the war in Ukraine, there is Corona, an arguably inevitable recession, and the energy crisis - not to mention long-standing challenges such as the fight against cancer and climate change. Companies want to help solve these problems, and BioNTech is one of these companies. The Wiesbaden-based Company was not only successful in the fight against COVID-19. They are currently taking on cancer. And the CEO has recently been very positive. Almonty Industries wants to help reduce dependence on raw materials from China and Russia, and one Company has already given it long-term purchase guarantees. And Plug Power wants to help solve the energy crisis and fight climate change. The recent numbers have disappointed, but analysts see upside potential. We look at the current performance of the three problem solvers.

Read

Commented by Nico Popp on October 17th, 2022 | 12:21 CEST

Defence Therapeutics, Commerzbank - Like BioNTech in March 2020?

  • Biotechnology
  • Turnaround

After price shocks and recession fears, the pandemic has also been back in the public eye since last week. German Health Minister Karl Lauterbach presented the vaccination strategy for the fall - and warned of an autumn wave. On the markets, the pandemic should be over, with a few exceptions. But Corona and BioNTech are suitable blueprints for other companies. We explain where else a special boom could occur and where investors are better off being cautious.

Read

Commented by André Will-Laudien on October 13th, 2022 | 14:10 CEST

Attention, turnaround: Bayer, BioNTech, Defence Therapeutics, MorphoSys - These biotech stocks are way down!

  • Biotechnology
  • Cancer

Even though more people are being diagnosed with cancer today, and the disease remains the leading cause of death, the number of people dying from cancer is trending downward. In recent years, respectively, survival rates have been steadily increasing. The relative proportion of survivors based on all cancer types in the US has increased from 50% to more than 67% over the past two decades, so today, two out of three patients with a serious disease are still alive after five years. In Europe, too, there has been an increase in 5-year survival rates for the most common cancer types. This is encouraging and draws attention to the oncology sector. Which biotech stocks are significant here and offer a good entry point?

Read

Commented by Fabian Lorenz on October 12th, 2022 | 11:33 CEST

TUI share soon to be a penny stock? BASF, BioNTech, Cardiol Therapeutics - buy or sell?

  • Biotechnology
  • chemicals

Buy or sell? It is not only the BASF share that is currently the subject of clearly differing opinions. While the gas price brake plans on Monday caused euphoria among investors and correspondingly rising prices for the shares of the chemical company, analysts from Goldman Sachs and Morgan Stanley continue to express pessimism. Experts are similarly cautious about the prospects for TUI. UBS even sees the share of the tourism group on the way to becoming a penny stock. Analysts are more optimistic about BioNTech, but the share is not making any headway at the moment. In contrast, experts see massive upside potential in the biotech gem Cardiol Therapeutics. Cash is now equal to market capitalization, and drug development is making progress.

Read

Commented by André Will-Laudien on October 12th, 2022 | 11:31 CEST

Biotech in the scope: BioNTech, XPhyto Therapeutics, MorphoSys, Valneva - The cards are reshuffled!

  • Biotechnology
  • Pharma

Cancer remains one of the greatest afflictions of our time, along with cardiovascular disease. Despite the tremendous progress already made in the fight against cancer, there remains an unmet medical need for many types of cancer. Cancer was responsible for nearly 10 million deaths worldwide in 2020. Other diseases, such as Alzheimer's and Parkinson's, also continue to be the focus of research. How is the biotech industry faring after the pandemic and during the stock market storm?

Read

Commented by Stefan Feulner on October 10th, 2022 | 10:43 CEST

BioNTech, Fonterelli GmbH & Co KGaA, Fonterelli SPAC 2 AG, MorphoSys - Bullish forecasts

  • Investments
  • Biotechnology
  • Covid19

The capital-intensive biotech and pharma sector has been stuck in a correction since the central banks changed their strategy at the beginning of the stock market year. In particular, vaccine manufacturers, which have exploded since the outbreak of COVID-19, have lost disproportionately in value since their highs in August of last year. However, the pandemic is likely to be with us for the next few years, albeit in a weakened form. The development of new drugs benefits companies that could now face a similar path as the vaccine producers.

Read